MedTrace Logo

Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer

NCT03180528 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-06-08

Study results available
· View outcomes & findings →

Summary

This phase 2 trial studies how well remetinostat works in treating patients with skin basal cell cancer. Remetinostat may slow the growth of basal cell cancer cells.

Conditions

  • Skin Basal Cell Carcinoma

Interventions

DRUG

Remetinostat

Applied topically under bandage occlusion

Sponsors & Collaborators

  • Medivir

    collaborator INDUSTRY

  • National Institutes of Health (NIH)

    collaborator NIH

  • American Skin Association

    collaborator OTHER

  • Kavita Sarin

    lead OTHER

Principal Investigators

  • Kavita Sarin · Stanford University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-07
Primary Completion
2020-07-07
Completion
2020-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03180528 on ClinicalTrials.gov